Entera Bio Ltd. is a biopharmaceutical firm in the clinical development phase, dedicated to creating and marketing oral medications composed of large ...
Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer
Est. EPS $-0.08 · Revenue $0.00 · 1 analysts
Est. EPS $-0.09 · Revenue $0.00 · 1 analysts
Est. EPS $-0.34 · Revenue $54.58M · 1 analysts
Est. EPS $-0.13 · Revenue $0.00 · 1 analysts
| Metric | Latest | YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength. | QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes. |
|---|---|---|---|
| RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three). | $42000 | -76.8% | — |
| Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day. | $-11.4M | -19.9% | -108.6% |
| Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials. | 0.0% | -100.0% | — |
| Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on). | -27450.0% | -418.4% | — |
| Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales. | -27235.7% | -416.7% | — |
| Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock. | $-7.5M | -9.6% | -12.2% |
| FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine. | -17802.4% | -372.4% | — |
| Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe. | 3.7% | +11.1% | +39.5% |
| Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking. | 3.23x | -57.7% | +13.3% |
| Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground. | $16.0M | +70.3% | +48.4% |
| Metric | Annual (A vs E) | Annual Surprise | Quarter (A vs E) | Quarter Surprise |
|---|---|---|---|---|
| EPS Surprise | -0.25 vs -0.28 | +10.7% | -0.14 vs -0.08 | -75.0% |
| Revenue Surprise | $42000 vs $42000 | 0.0% | — | — |
| Date | Executive | Title | Security | Side | Shares | Price |
|---|---|---|---|---|---|---|
| Aug 18, 2026 | Camisasca Riccardo Paolo | officer | — | — | 0 | — |
| Aug 7, 2026 | Malca Yonatan | director | Ordinary Shares, par value NIS 0.0000769 per share | A | 22,815 | — |
| Aug 7, 2026 | Taitel Haya | director | Ordinary Shares, par value NIS 0.0000769 per share | A | 20,790 | — |
| Aug 7, 2026 | Ellis Sean | director | Ordinary Shares, par value NIS 0.0000769 per share | A | 20,034 | — |
| Aug 7, 2026 | Ellis Sean | director | Stock Option (right to buy) | A | 40,000 | $1.37 |
| Name | Title | Compensation | Gender | Year Born | Status |
|---|---|---|---|---|---|
Miranda J. Toledano | Chief Executive Officer & Director | USD 562,000 | Female | 1977 | Active |
Riccardo Paolo Camisasca | Chief Medical Officer | USD 355,000 | Male | — | Active |
Hillel Galitzer | Chief Operating Officer | USD 307,000 | — | 1978 | Active |
Gregory Burshtein | Chief of Research & Development | USD 254,000 | — | 1977 | Active |
Dana Yaacov-Garbeli | Chief Financial Officer | USD 226,000 | Female | 1983 | Active |
Michele McDermott | MD & EVP of Medical Affairs | — | Female | — | Active |
Constantin Itin | Head of Biopharmaceutics & Bioanalytics | — | — | — | Active |
Rachel Wagman | Chief Clinical Advisor | — | — | — | Active |
Cherin Smith | Executive Vice President & Head of Clinical Operations | — | Female | — | Active |
TEL AVIV, Israel, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides, today announced that the Company's Chief Executive Officer, Miranda Toledano, will be participating in the following upcoming fall investor conferences:
TEL AVIV, Israel, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides, today announced that the Company's Chief Executive Officer, Miranda Toledano, will be participating in the following upcoming fall investor conferences: 2026 Cantor Global Healthcare Conference Fireside Chat: September 10, 2026 at 1:00 p.m.
Dr. Camisasca joins Entera with 30 years of global pharmaceutical research and clinical development experience including roles at Sumitomo Pharma, Takeda, and Novartis Appointment further strengthens Entera's clinical execution team and late-stage development capabilities ahead of planned EB613 Phase 3 initiation TEL AVIV, Israel, Aug. 18, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides, today announced the appointment of Riccardo Paolo Camisasca, M.D.
Entera Bio NASDAQ: ENTX plans to begin a Phase 3 study of its oral osteoporosis candidate EB613 after reaching agreement with the U.S. Food and Drug Administration on a 12-month, placebo-controlled registrational trial, Chief Executive Officer Miranda Toledano said during a discussion hosted by Canaccord Genuity.
U.S. Food and Drug Administration (FDA) Alignment on 12-Month Registrational Phase 3 Study to Support NDA for EB613 - the First Oral Anabolic Tablet in Development for Postmenopausal Women with Osteoporosis
